We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 03, 2021

Neoadjuvant Durvalumab With or Without Stereotactic Body Radiotherapy in Patients With Early-Stage NSCLC

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Neoadjuvant Durvalumab With or Without Stereotactic Body Radiotherapy in Patients With Early-Stage Non-Small-Cell Lung Cancer: A Single-Centre, Randomised Phase 2 Trial
Lancet Oncol 2021 May 17;[EPub Ahead of Print], NK Altorki, TE McGraw, AC Borczuk, et al

Further Reading